Effect of Bimagrumab on body composition: a systematic review and meta-analysis.

What It Covers

Researchers studied Bimagrumab in this meta-analysis publication.

The primary objective of this meta-analysis is to evaluate the impact of bimagrumab treatment on both physical performance and body composition among patients diagnosed with sarcopenia.

Why It Was Studied

Current standard treatments such as dietary interventions and exercise programs are often unsustainable.

Who the Included Studies Covered

The researchers systematically searched PubMed, Ovid/Medline, Web of Science, and the Cochrane Library databases up to June 2024 using appropriate Medical Subject Headings (MeSH) terms and keywords related to bimagrumab and sarcopenia.

Eligible studies were randomized controlled trials (RCTs) that assessed the effects of bimagrumab on physical performance (e.g., muscle strength, gait speed, six-minute walk distance) and body composition (e.g., muscle volume, fat-free body mass, fat body mass) in patients with sarcopenia.

How the Review Was Done

This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Data extraction was independently performed by two reviewers using a standardized form, with discrepancies resolved through discussion or consultation with a third reviewer.

What Was Measured

PubMed files the paper under topics including Body Composition, Sarcopenia, Antibodies, Monoclonal, Humanized, Muscle Strength and Randomized Controlled Trials as Topic.

The authors tagged it with the keywords Bimagrumab, Fat body mass, Fat-free body mass, Physical performance, Thigh muscle volume and Treatment modality.

What This Means in Plain Language

This is a meta-analysis of Bimagrumab.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Aging clinical and experimental research), a journal based in Germany.

More context: the Bimagrumab compound page, all human trials.